Clinical trials: Acute Decompensated Heart Failure
Acute Heart Failure
Loop Diuretics Administration and Acute Heart Failure
Intravenous loop diuretics is the therapy most commonly used to treat pulmonary congestion and systemic fluid overload. In theory, continuous infusion should allow for a more consistent diuresis, avoiding the sodium reabsorption…
- Trial name
- diurHF (NCT01441245)
- Testing
- furosemide infusion
- Where
- Italy
- Volunteers
- 57 people
- Sponsor
- University of Siena
Heart Failure
Integrated Tele-monitoring and Patient-centric Health Coaching Strategy in Patients Hospitalized With Heart Failure
This study evaluates the effectiveness of remote tele-monitoring and health coaching in helping to reduce hospitalizations in heart failure patients.
- Trial name
- Tele-HC (NCT02391987)
- Testing
- Tele-monitoring and health coaching
- Where
- 5 sites in United States
- Volunteers
- 112 people
- Sponsor
- Mayo Clinic
Congestive Heart Failure
Sub-Q Versus IV Furosemide in Acute Heart Failure
This study evaluates the clinical efficacy of subcutaneously administered Furosemide Injection Solution versus intravenous administration of Furosemide Injection, United States Pharmacopeia (USP) in adult patients presenting to a…
- Trial name
- NCT02579057
- Testing
- Furosemide Injection Solution (SCP-101), Furosemide Injection Solution, USP
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Johns Hopkins University
Acute Decompensated Heart Failure, Volume Overload
Acetazolamide in Decompensated Heart Failure With Volume OveRload (ADVOR)
This clinical research study is being conducted in multiple hospitals in Belgium and approximately 519 patients with acute decompensated heart failure are expected to participate.
- Trial name
- Advor (NCT03505788)
- Testing
- Acetazolamide
- Where
- Belgium
- Volunteers
- 519 people
- Sponsor
- Ziekenhuis Oost-Limburg
Acute Decompensated Heart Failure
The Clinical Study of the Safety and Efficacy of Istaroxime in Treatment of Acute Decompensated Heart Failure
To assess the safety, tolerability and efficacy of two different doses of istaroxime, a new agent with lusitropic and inotropic activities that improves the cardiac contraction-relaxation cycle.
- Trial name
- NCT02617446
- Testing
- Istaroxime
- Where
- 11 sites in China, Italy
- Volunteers
- 120 people
- Sponsor
- Windtree Therapeutics
Acute Decompensated Heart Failure
REducing 30-day ADMIssions in posT-discharge Subjects (READMIT)
The purpose of this observational study is to collect and characterize multiple physiologic data from a broad subset of subjects with acute heart failure (HF) Changes in physiologic data are expected to correlate with 30-day…
- Trial name
- READMIT-HF (NCT01574144)
- Testing
- AVIVO™ PiiX Patch Monitor System
- Where
- 8 sites in United States, Australia
- Volunteers
- 70 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Acute Decompensated Heart Failure, Sleep Disordered Breathing
Cardiovascular Improvements With MV ASV Therapy in Heart Failure
The aim of the study is to compare the effects of MV targeted ASV in addition to optimized medical therapy versus optimized medical therapy alone at 6 months in patients with acute decompensated HF.
- Trial name
- CAT-HF (NCT01953874)
- Testing
- MV ASV, Optimized Medical Treatment
- Where
- 15 sites in United States, Germany
- Volunteers
- 126 people
- Sponsor
- ResMed
Heart Failure Acute, Heart Failure，Congestive
Effects of Empagliflozin on Clinical Outcomes in Patients With Acute Decompensated Heart Failure
Acute decompensated heart failure is the fastest growing disease in the world and the leading cause of hospital admissions worldwide.
- Conditions
- Heart Failure Acute, Heart Failure，Congestive, Heart Failure; With Decompensation
- Trial name
- EMPA-RESPONSE (NCT03200860)
- Testing
- Empagliflozin 10 MG
- Where
- 5 sites in Netherlands
- Volunteers
- 80 people
- Sponsor
- University Medical Center Groningen
Acute Decompensated Heart Failure
The Hemodynamic Effects of SGLT2i in Acute Decompensated Heart Failure
The main purpose of this study is to observe hemodynamic effects of initiating sodium-glucose co-transporter 2 inhibitors (SGLT2i) in patients admitted to the intensive care unit (ICU) with acute decompensated heart failure.
- Trial name
- NCT05346653
- Testing
- SGLT2i, No SGLT2i
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Chicago
Acute Decompensated Heart Failure
Assessment of Biomarkers and Cardiorenal Syndrome in Acute Decompensated Heart Failure With Vasodilator Therapy
The purpose of this study is to determine whether Nesiritide is more effective than nitroglycerin in modifying inflammatory and neurohormonal biomarkers without renal toxicity when proper infusion duration is administered.
- Trial name
- ABC-HFT (NCT00842023)
- Testing
- Nesiritide, Nitroglycerin
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- Western University of Health Sciences
Acute Decompensated Heart Failure
Assessment of Coronary Flow Reserve in Heart Failure Patients After Ultrafiltration Versus Diuretics
The purpose of this research study is to compare the effects (good and bad) of ultrafiltration treatment with standard intravenous (in your vein) diuretic therapy (furosemide, torsemide, bumetanide) on your heart function and…
- Trial name
- NCT01457053
- Testing
- Loop diuretics (furosemide, torsemide, bumetanide), Ultrafiltration
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- University of Cincinnati
Heart Failure, Cardiac Failure
Study of Heart Failure Hospitalizations After Aquapheresis Therapy Compared to Intravenous (IV) Diuretic Treatment
The purpose of the research is to determine if patients have fewer Heart Failure (HF) events after receiving Aquapheresis (AQ) therapy compared to intravenous (IV) diuretics up to 90 days of discharge from the hospital.
- Conditions
- Heart Failure, Cardiac Failure, Acute Decompensated Heart Failure (ADHF)
- Trial name
- AVOID-HF (NCT01474200)
- Testing
- Isolated veno-venous ultrafiltration (AQ), IV Loop Diuretics (LD)
- Where
- 38 sites in United States
- Volunteers
- 224 people
- Sponsor
- Nuwellis, Inc.
Heart Failure, Congestive
A Method Validation Study for Evaluation of Novel Treatments Limiting Pulmonary Oedema in Cardiac Failure
Transient receptor potential vanilloid 4 (TRPV4) channel blockade may be promising in the treatment of pulmonary oedema and dyspnoea in heart failure (HF) and acute decompensated heart failure (ADHF) patients by re-establishing…
- Trial name
- NCT02135861
- Testing
- DCE-MRI scans, Gadobutrol
- Where
- United Kingdom
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Heart Failure, Diabetes
Thiamine and Acute Decompensated Heart Failure: Pilot Study
Heart failure remains an increasing cause of morbidity and mortality in the United States even in the face of recent advances in the treatment of cardiovascular disease.
- Trial name
- NCT00680706
- Testing
- Thiamine
- Where
- 2 sites in United States
- Volunteers
- 131 people
- Sponsor
- Baystate Medical Center
Acute Decompensated Heart Failure
Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve Decongestion Management System (DMS)
The objective of this study is to prospectively compare decongestive therapy administered by the Reprieve DMS system to Optimal Diuretic Therapy (ODT) in the treatment of patients diagnosed with acute decompensated heart failure…
- Trial name
- FASTR (NCT05174312)
- Testing
- Reprieve Decongestion Management System, Diuretic
- Where
- 16 sites in United States
- Volunteers
- 100 people
- Sponsor
- Reprieve Cardiovascular, Inc
Heart Failure, Decompensated Heart Failure
A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure
A randomized, double-blinded, placebo-controlled study of continuous 6-hour IV infusions of CXL-1427 in hospitalized patients with systolic heart failure.
- Conditions
- Heart Failure, Decompensated Heart Failure, Acute Heart Failure
- Trial name
- NCT02157506
- Testing
- CXL-1427
- Where
- 35 sites in United States, Germany and 3 more
- Volunteers
- 70 people
- Sponsor
- Bristol-Myers Squibb
Acute Decompensated Heart Failure, Congestive Heart Failure
Six Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality in Patients With Acute Decompensated Heart Failure
This study evaluated the effect of early initiation of aliskiren therapy, compared to standard therapy, in the reduction of cardiovascular death and heart failure re-hospitalization events within 6 months, in congestive heart…
- Trial name
- ASTRONAUT (NCT00894387)
- Testing
- Aliskiren
- Where
- 308 sites in United States, Argentina and 22 more
- Volunteers
- 1,639 people
- Sponsor
- Novartis Pharmaceuticals
Acute Decompensated Heart Failure
Oral Metolazone and Intermittent Intravenous Furosemide Versus Continuous Infusion Furosemide in Acute Heart Failure
The purpose of this prospective, randomized, open-label study is to compare two diuretic strategies in patients with acute decompensated heart failure (ADHF): the addition of an oral thiazide diuretic to intravenous bolus (IVB)…
- Trial name
- NCT00904488
- Testing
- Addition of oral Metolazone, Furosemide dose escalation
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of North Carolina, Chapel Hill
Acute Heart Failure
Subcutaneous Furosemide in Acute Decompensated Heart Failure Pilot
The Pilot study is designed to evaluate the overall safety and feasibility of a strategy based on subcutaneous delivery of furosemide. It will be used to inform the subsequent evaluation phase of the study (separate protocol).
- Trial name
- SUBQ-Pilot (NCT02877095)
- Testing
- Furosemide
- Where
- 5 sites in United States
- Volunteers
- 40 people
- Sponsor
- Adrian Hernandez
Acute Decompensated Heart Failure, Acute Kidney Injury
Acute Kidney Injury Neutrophil Gelatinase-Associated Lipocalin Evaluation of Symptomatic Heart Failure Study
AKINESIS is a clinical study to assess the utility of blood and urine NGAL tests in predicting worsening kidney function in patients who present with acute heart failure (AHF) and who are treated with diuretics.
- Trial name
- AKINESIS (NCT01291836)
- Where
- 13 sites in United States, Greece and 5 more
- Volunteers
- 930 people
- Sponsor
- Alere San Diego